BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling.
Bone marrow mesenchymal stem cell
Differentiation
Exosomes
Radiation
β-Catenin
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
21
10
2018
accepted:
20
12
2018
revised:
12
12
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
17
1
2019
Statut:
epublish
Résumé
Radiotherapy to cancer patients is inevitably accompanied by normal tissue injury, and the bone is one of the most commonly damaged tissues. Damage to bone marrow mesenchymal stem cells (BM-MSCs) induced by radiation is thought to be a major cause of radiation-induced bone loss. Exosomes exhibit great therapeutic potential in the treatment of osteoporosis, but whether exosomes are involved in radiation-induced bone loss has not been thoroughly elucidated to date. The main purpose of this study is to investigate the role of exosomes derived from BM-MSCs in restoring recipient BM-MSC function and alleviating radiation-induced bone loss. BM-MSC-derived exosomes were intravenously injected to rats immediately after irradiation. After 28 days, the left tibiae were harvested for micro-CT and histomorphometric analysis. The effects of exosomes on antioxidant capacity, DNA damage repair, proliferation, and cell senescence of recipient BM-MSCs were determined. Osteogenic and adipogenic differentiation assays were used to detect the effects of exosomes on the differentiation potential of recipient BM-MSCs, and related genes were measured by qRT-PCR and Western blot analysis. β-Catenin expression was detected at histological and cytological levels. BM-MSC-derived exosomes can attenuate radiation-induced bone loss in a rat model that is similar to mesenchymal stem cell transplantation. Exosome-treated BM-MSCs exhibit reduced oxidative stress, accelerated DNA damage repair, and reduced proliferation inhibition and cell senescence-associate protein expression compared with BM-MSCs that exclusively received irradiation. Following irradiation, exosomes promote β-catenin expression in BM-MSCs and restore the balance between adipogenic and osteogenic differentiation. Our findings indicate that BM-MSC-derived exosomes take effects by restoring the function of recipient BM-MSCs. Therefore, exosomes may represent a promising cell-free therapeutic approach for the treatment of radiation-induced bone loss.
Sections du résumé
BACKGROUND
Radiotherapy to cancer patients is inevitably accompanied by normal tissue injury, and the bone is one of the most commonly damaged tissues. Damage to bone marrow mesenchymal stem cells (BM-MSCs) induced by radiation is thought to be a major cause of radiation-induced bone loss. Exosomes exhibit great therapeutic potential in the treatment of osteoporosis, but whether exosomes are involved in radiation-induced bone loss has not been thoroughly elucidated to date. The main purpose of this study is to investigate the role of exosomes derived from BM-MSCs in restoring recipient BM-MSC function and alleviating radiation-induced bone loss.
METHODS
BM-MSC-derived exosomes were intravenously injected to rats immediately after irradiation. After 28 days, the left tibiae were harvested for micro-CT and histomorphometric analysis. The effects of exosomes on antioxidant capacity, DNA damage repair, proliferation, and cell senescence of recipient BM-MSCs were determined. Osteogenic and adipogenic differentiation assays were used to detect the effects of exosomes on the differentiation potential of recipient BM-MSCs, and related genes were measured by qRT-PCR and Western blot analysis. β-Catenin expression was detected at histological and cytological levels.
RESULTS
BM-MSC-derived exosomes can attenuate radiation-induced bone loss in a rat model that is similar to mesenchymal stem cell transplantation. Exosome-treated BM-MSCs exhibit reduced oxidative stress, accelerated DNA damage repair, and reduced proliferation inhibition and cell senescence-associate protein expression compared with BM-MSCs that exclusively received irradiation. Following irradiation, exosomes promote β-catenin expression in BM-MSCs and restore the balance between adipogenic and osteogenic differentiation.
CONCLUSIONS
Our findings indicate that BM-MSC-derived exosomes take effects by restoring the function of recipient BM-MSCs. Therefore, exosomes may represent a promising cell-free therapeutic approach for the treatment of radiation-induced bone loss.
Identifiants
pubmed: 30646958
doi: 10.1186/s13287-018-1121-9
pii: 10.1186/s13287-018-1121-9
pmc: PMC6334443
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Commentaires et corrections
Type : ErratumIn
Références
Semin Cell Dev Biol. 2015 Apr;40:82-8
pubmed: 25765629
Stem Cells Transl Med. 2016 May;5(5):683-93
pubmed: 26987353
Nat Rev Endocrinol. 2010 Nov;6(11):629-36
pubmed: 20820194
J Clin Invest. 2006 May;116(5):1202-9
pubmed: 16670761
Mol Med Rep. 2016 Jan;13(1):213-23
pubmed: 26572960
Theranostics. 2018 Jan 1;8(1):237-255
pubmed: 29290805
Int J Biol Sci. 2015 Jan 12;11(2):238-45
pubmed: 25632267
Stem Cells Transl Med. 2015 May;4(5):513-22
pubmed: 25824139
Rev Endocr Metab Disord. 2015 Jun;16(2):131-9
pubmed: 25557611
Ann Hematol. 2018 Apr;97(4):697-707
pubmed: 29349655
J Cereb Blood Flow Metab. 2018 May;38(5):767-779
pubmed: 28524762
Pediatr Transplant. 2007 Jun;11(4):379-87
pubmed: 17493217
Cancer Treat Rev. 2015 Nov;41(9):798-808
pubmed: 26410578
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
Cell. 2012 Dec 21;151(7):1542-56
pubmed: 23260141
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3962-3970
pubmed: 29949171
Int J Mol Sci. 2018 Jan 25;19(2):
pubmed: 29370110
Cell. 1997 May 30;89(5):747-54
pubmed: 9182762
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3589-90
pubmed: 25762069
Front Genet. 2017 Dec 19;8:220
pubmed: 29312442
Circ Res. 2010 Oct 1;107(7):913-22
pubmed: 20671238
J Orthop Surg Res. 2016 Jan 07;11:3
pubmed: 26739584
Int J Cardiol. 2016 Aug 1;216:173-85
pubmed: 27156061
Gerontology. 2013;59(6):557-63
pubmed: 23970150
Cancer. 2010 Feb 1;116(3):625-30
pubmed: 20052724
Stem Cells. 2017 Apr;35(4):851-858
pubmed: 28294454
Int J Radiat Biol. 2012 May;88(5):393-404
pubmed: 22348537
Plast Reconstr Surg. 2000 Oct;106(5):1049-61
pubmed: 11039376
Cell Metab. 2015 Oct 6;22(4):606-18
pubmed: 26365178
Stem Cell Res Ther. 2013 Apr 25;4(2):34
pubmed: 23618405
Semin Radiat Oncol. 2009 Apr;19(2):133-9
pubmed: 19249651
Mol Ther. 2017 Feb 1;25(2):465-479
pubmed: 28089078
Oncotarget. 2013 Nov;4(11):2057-66
pubmed: 24185202
Mol Aspects Med. 2018 Apr;60:123-128
pubmed: 28965750
Gastroenterology. 2009 Mar;136(3):978-89
pubmed: 19135996
Bone. 2012 Feb;50(2):477-89
pubmed: 21872687
Circ Res. 2015 Jun 19;117(1):52-64
pubmed: 25904597
Curr Osteoporos Rep. 2013 Dec;11(4):299-304
pubmed: 24057133
Exp Mol Med. 2017 Jun 16;49(6):e346
pubmed: 28620221
Stem Cell Res Ther. 2015 May 27;6:104
pubmed: 26012584
JAMA. 2005 Nov 23;294(20):2587-93
pubmed: 16304072
Stem Cells. 2015 Jun;33(6):1915-26
pubmed: 25847389
Tissue Eng Part C Methods. 2015 Feb;21(2):112-22
pubmed: 24918644
Hum Gene Ther. 2017 Feb;28(2):179-189
pubmed: 27802778
Radiother Oncol. 2016 Mar;118(3):430-6
pubmed: 26993414
Bone. 2004 Jan;34(1):148-56
pubmed: 14751572
Oncotarget. 2015 Apr 10;6(10):8155-66
pubmed: 25544750
J Control Release. 2018 Mar 10;273:86-98
pubmed: 29373816
Haematologica. 2016 Aug;101(8):985-94
pubmed: 27175026
Mol Cell Biol. 2007 Jan;27(2):743-57
pubmed: 17060461
Int J Biol Sci. 2017 Feb 6;13(2):232-244
pubmed: 28255275
J Bone Miner Res. 2012 Apr;27(4):749-59
pubmed: 22190044
Med Sci Monit. 2016 Jan 21;22:226-33
pubmed: 26795027
Regen Med. 2011 Jul;6(4):481-92
pubmed: 21749206
Cell Death Dis. 2013 Oct 10;4:e844
pubmed: 24113178
Int J Biol Sci. 2016 May 25;12(7):836-49
pubmed: 27313497
Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):
pubmed: 23209147